LRMR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Larimar Therapeutics Inc (LRMR) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has received positive analyst ratings and has a promising regulatory submission in the pipeline, the technical indicators and financial performance do not currently support a strong entry point. The lack of significant trading signals and recent news further suggests a wait-and-see approach.
The MACD is negative and expanding, indicating a bearish trend. RSI is neutral at 25.618, and moving averages are converging, showing no clear directional bias. The stock is trading near its support level (S1: 4.451), but there is no strong upward momentum.
Analysts have raised price targets recently, with Wedbush and Citi maintaining positive ratings.
Technical indicators suggest bearish momentum, and there is no recent news or congress trading data to drive immediate interest.
In Q4 2025, the company reported no revenue growth (0% YoY) and a net loss of -$62.5M, which improved by 116.83% YoY. EPS also improved to -0.73, up 62.22% YoY, but the financials remain weak overall.
Analysts have raised price targets recently, with Wedbush increasing its target to $13 and Citi raising its target to $14. Both firms maintain positive ratings, citing the company's regulatory progress and cash runway extending into Q2 2027.
